I feel your pain---foolish to hold onto this---you think I care if you sell, you won't influence price; just trying to give some friendly advice
1- company has takeover premium built into price 2-recent acquisition will be dilutive 3-said during cc subscriber base will not grow over rest of the year 4-stepping up marketing expenses 5-there are lots of real cheap cyclicals which I do own-EMR,FLR,CBI,COH
I agree with your first point: The price is anticipating the offer. I have commented on this in a couple of places, pointing out the call option pricing indicates the market is 95% confidence of a $35 price tag. This is not unique to ACOM. Thus the (misguided)adage 'buy on the rumor, sell on the news'.
The rest of your points are weak. Just because a deal may be dilutive in the short run doesn't make it a bad deal, or one which will have long term negative impact. The same logic applies to increased market expenses: It helps the company to grow. I didn't listen to the cc so I can't comment on your third point, and I don't give a flying rat's rear end about what you own.
But thanks for taking your meds and making an attempt at a coherent contribution